2,2,2-三氟乙基吡嗪-2-羧酸酯 | 139244-46-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2,2,2-三氟乙基吡嗪-2-羧酸酯
• 英文名称: 2,2,2-trifluoroethyl pyrazinoate
• 英文别名: 2-pyrazinecarboxylic acid 2,2,2-trifluoroethyl ester；β, β, β-trifluoroethyl pyrazinoate；Pyrazinecarboxylic acid, 2,2,2-trifluoroethyl ester；2,2,2-trifluoroethyl pyrazine-2-carboxylate
• CAS: 139244-46-5
• 化学式: C₇H₅F₃N₂O₂
• mdl: MFCD01693960
• 分子量: 206.124
• InChiKey: ULSGTKAIZYJJHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-甲酸吡嗪 在 吡啶 、 氯化亚砜 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 3.0h， 生成 2,2,2-三氟乙基吡嗪-2-羧酸酯
  参考文献：
  名称：

  一系列吡嗪酸酯的抗分枝杆菌活性。

  摘要：

  已经制备了一系列吡嗪酸酯，并评估了其体外抗分枝杆菌活性。几种吡嗪酸酯具有比一线抗结核剂吡嗪酰胺对结核分枝杆菌易感分离株更好的活性以及对耐吡嗪酰胺分离株的活性。与吡嗪酰胺相比，每种生物在每种pH下的最低抑菌浓度（MIC）均低。该酯具有抗牛津分枝杆菌和堪萨斯分枝杆菌（对吡嗪酰胺有抗性的两种）的活性，但对鸟分枝杆菌复合物没有活性。

  DOI：

  10.1021/jm00085a007

文献信息

• Regioselective enzymatic acylation as a tool for producing solution-phase combinatorial libraries
  作者：Vadim V. Mozhaev、Cheryl L. Budde、Joseph O. Rich、Alexander Ya. Usyatinsky、Peter C. Michels、Yuri L. Khmelnitsky、Douglas S. Clark、Jonathan S. Dordick

  DOI：10.1016/s0040-4020(98)00129-x

  日期：1998.4

  complete lack of regioselectivity. The enzymatic strategy was applied successfully to produce a solution phase combinatorial library of 167 distinct selectively acylated derivatives of bergenin on a robotic workstation in a 96-well plate format. General applicability of the automated combinatorial biocatalysis strategy is discussed.

  已经开发出了一种简单的组合策略，用于对多功能先导化合物进行顺序区域选择性酶促酰化，并使用多羟基化类黄酮，佛手素作为模型进行了证明。该方法基于不同酶在不影响其他相似功能基团的情况下将前导分子上的不同位点区域选择性酰化的能力。与酶促酰化形成鲜明对比的是，常规化学酰化方法显示出几乎完全缺乏区域选择性。酶促策略已成功应用，以96孔板形式在机器人工作站上生成了167种不同的，选择性的酰化卑尔根的衍生物的溶液相组合文库。讨论了自动组合生物催化策略的一般适用性。
• [EN] METHODS FOR PREPARING DOXORUBICIN DERIVATIVES<br/>[FR] PROCEDES PERMETTANT DE PREPARER DES DERIVES DE DOXORUBICINE
  申请人：ALBANY MOLECULAR RES INC

  公开号：WO2003057687A1

  公开（公告）日：2003-07-17

  The present invetion relates to a process for preparation of a product compound of formula (I), where R1 is an acyl group. The process involves reacting a starting compound of formula (II), with an activated acyl donor compound in the presence of a non-chemically modified lipase, under conditions effective to produce the product compound.
• [EN] METHODS FOR PREPARING ANTHRACYCLINONE DERIVATIVES AND ANTHRACYCLINONE DERIVATIVES PER SE<br/>[FR] METHODES PERMETTANT DE PREPARER DES DERIVES D'ANTHRACYCLINONE ET LESDITS DERIVES D'ANTHRACYCLINONE
  申请人：ALBANY MOLECULAR RES INC

  公开号：WO2003057896A1

  公开（公告）日：2003-07-17

  The present invention relates to a process for preparation of a product compound of the Formula (I), where R1 is an acyl group, R2 is H, an N-alkylated amino sugar, or a non-basic sugar moiety, and R3 is H, OH, or OCH3. The process involves reacting a starting compound of the Formula (II) with an acyl donor compound in the presence of a non-chemically modified lipase, under conditions effective to produce the product compound. Another aspect of the present invention relates to a compound of the following Formula (III), where: R1 is an acyl radical of a carboxylic acid selected from the group consisting of: polyethylene glycol acetic acid and polyunsaturated fatty acid; and R2 = 2,6-dideoxy-2-fluoro-α-talopyranosyl; 3-trifluoroacetylamino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl; or 3-deamino-3-(2'-pyrroline-1'-yl)-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl; or a pharmaceutically acceptable salt thereof. The present invention also relates to a compound of the Formula (IV) where n is 4 or 5, or a pharmaceutically acceptable salt thereof. Another aspect of the present invention relates to a compound of the Formula (V) where: R1 is an acyl group, R2 is 3-substituted allyloxycarbonylamino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl, R3 is H, OH, or OCH3.
• [EN] BIOCATALYTIC PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED PRAMIPEXOLE<br/>[FR] PROCEDE BIOCATALYTIQUE DE FABRICATION DE PRAMIPEXOLE ENRICHI ENANTIOMERIQUEMENT
  申请人：AMR TECHNOLOGY INC

  公开号：WO2006012277A2

  公开（公告）日：2006-02-02

  biocatalytic process for preparing enantiomerically enriched pramipexole and pramipexole precursors are disclosed.